Explore more publications!

Press Releases

Hemp Seed Oil Market Set for Rapid Expansion at 19.3% CAGR, Says Towards FnB
Anemometer Market Surges as Renewable Energy, Aviation & Smart Weather Systems Drive Demand 2025-32 | DataM Intelligence
Preferred Hotels & Resorts Expands Global Portfolio With 21 New Members
ISS wins full IFS contract for major life sciences and pharmaceutical company in Switzerland
Natural Carotenoids Market Expected to Reach USD 708.03 Million by 2035 Amid Rising Functional Nutrition Trends
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR
Envision Launches Dubhe, Shaping the AI Energy System with the World's First Energy Foundation Model
Protein Supplements Market Size to Worth USD 70.24 Billion by 2035 | Towards FnB
The Arctic This Week Take Five: Week of 19 January, 2026

The Arctic This Week Take Five: Week of 19 January, 2026

Europe Contract Catering Market Set for USD 70.73 Bn Growth as Demand Shifts Across Corporate, Healthcare, and Education
The OpenHW Foundation unveils the first industry-ready RISC-V ecosystem to advance European digital sovereignty
Sanity United Launches Integrated Platform Combining AI-Powered Errands, Electric Mobility, and Renewable Energy
European Rail Atlas from Ramboll identifies long-term investment as decisive lever to achieve Europe’s rail ambitions
E1 welcomes 12Build as part of its global construction procurement platform
Heimdal Achieves OPSWAT Gold Certification for Anti-Malware
Jabra reinforces headset leadership with new Evolve3 Series, professional audio engineered for both work and leisure
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Prime Minister Carney builds resilient partnerships and attracts new investments at the World Economic Forum Annual Meeting

Prime Minister Carney builds resilient partnerships and attracts new investments at the World Economic Forum Annual Meeting

AI in Cultured Meat Market Size to Exceed USD 573.45 Million by 2035 | Towards FnB
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions